These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30419272)

  • 1. Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D
    DiPalma D; Rezvani AH; Willette B; Wells C; Slade S; Hall BJ; Levin ED
    Pharmacol Biochem Behav; 2019 Jan; 176():16-22. PubMed ID: 30419272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic interactive treatments of serotonin 5HT
    Willette BKA; Nangia A; Howard S; DiPalma D; McMillan C; Tharwani S; Evans J; Wells C; Slade S; Hall BJ; Rezvani AH; Levin ED
    Pharmacol Biochem Behav; 2019 Nov; 186():172766. PubMed ID: 31470021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
    Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE
    J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of insular cortex D₁ and D₂ dopamine receptors in nicotine self-administration in rats.
    Kutlu MG; Burke D; Slade S; Hall BJ; Rose JE; Levin ED
    Behav Brain Res; 2013 Nov; 256():273-8. PubMed ID: 23948214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats.
    Hall BJ; Slade S; Allenby C; Kutlu MG; Levin ED
    Neuropharmacology; 2015 Dec; 99():689-95. PubMed ID: 25797492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dextromethorphan interactions with histaminergic and serotonergic treatments to reduce nicotine self-administration in rats.
    Briggs SA; Hall BJ; Wells C; Slade S; Jaskowski P; Morrison M; Rezvani AH; Rose JE; Levin ED
    Pharmacol Biochem Behav; 2016 Mar; 142():1-7. PubMed ID: 26704812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lorcaserin (Belviq
    Jacobs DS; Barkin CE; Kohut MR; Bergman J; Kohut SJ
    Drug Alcohol Depend; 2017 Dec; 181():94-101. PubMed ID: 29040827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.
    Levin ED; Slade S; Johnson M; Petro A; Horton K; Williams P; Rezvani AH; Rose JE
    Eur J Pharmacol; 2008 Dec; 600(1-3):93-7. PubMed ID: 18950618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs.
    Cousins V; Rose JE; Levin ED
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():200-5. PubMed ID: 24953434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evidence for combining the 5-HT
    Fletcher PJ; Li Z; Silenieks LB; MacMillan C; DeLannoy I; Higgins GA
    Addict Biol; 2019 May; 24(3):376-387. PubMed ID: 29498158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic glutamate NMDA antagonist treatment attenuates dopamine D
    Natarajan S; Abass G; Kim L; Wells C; Rezvani AH; Levin ED
    Pharmacol Biochem Behav; 2024 Jan; 234():173678. PubMed ID: 37979731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
    Higgins GA; Silenieks LB; Rossmann A; Rizos Z; Noble K; Soko AD; Fletcher PJ
    Neuropsychopharmacology; 2012 Apr; 37(5):1177-91. PubMed ID: 22189292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
    Gannon BM; Sulima A; Rice KC; Collins GT
    J Pharmacol Exp Ther; 2018 Mar; 364(2):359-366. PubMed ID: 29217539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histamine H(1) antagonist treatment with pyrilamine reduces nicotine self-administration in rats.
    Levin ED; Slade S; Wells C; Pruitt M; Cousins V; Cauley M; Petro A; Hampton D; Rose J
    Eur J Pharmacol; 2011 Jan; 650(1):256-60. PubMed ID: 20951696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats.
    Levin ED; Hall BJ; Chattopadhyay A; Slade S; Wells C; Rezvani AH; Rose JE
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3009-15. PubMed ID: 27318988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of nicotinic acetylcholine or dopamine D1-like receptors in the central nucleus of the amygdala or the bed nucleus of the stria terminalis does not precipitate nicotine withdrawal in nicotine-dependent rats.
    Jonkman S; Markou A
    Neurosci Lett; 2006 May; 400(1-2):140-5. PubMed ID: 16563623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats.
    Ohmura Y; Jutkiewicz EM; Zhang A; Domino EF
    Pharmacol Biochem Behav; 2011 Oct; 99(4):552-6. PubMed ID: 21624384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.